Free Trial

Actuate Therapeutics (NASDAQ:ACTU) Given New $20.00 Price Target at HC Wainwright

Actuate Therapeutics logo with Medical background

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) had its price target hoisted by investment analysts at HC Wainwright to $20.00 in a research note issued on Tuesday, Stock Target Advisor reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 119.54% from the stock's current price.

Separately, Craig Hallum started coverage on shares of Actuate Therapeutics in a report on Tuesday, April 22nd. They set a "buy" rating and a $21.00 price target on the stock.

Read Our Latest Analysis on ACTU

Actuate Therapeutics Price Performance

Shares of ACTU stock traded down $0.64 during mid-day trading on Tuesday, reaching $9.11. The stock had a trading volume of 63,307 shares, compared to its average volume of 49,889. The stock's 50-day moving average price is $8.98 and its two-hundred day moving average price is $8.43. Actuate Therapeutics has a 52-week low of $5.51 and a 52-week high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BIOS Capital Management LP bought a new stake in Actuate Therapeutics in the 4th quarter worth approximately $78,753,000. Voss Capital LP grew its holdings in shares of Actuate Therapeutics by 157.7% in the first quarter. Voss Capital LP now owns 142,381 shares of the company's stock worth $964,000 after acquiring an additional 87,135 shares during the period. Sigma Planning Corp increased its position in Actuate Therapeutics by 47.3% during the first quarter. Sigma Planning Corp now owns 23,675 shares of the company's stock valued at $160,000 after acquiring an additional 7,600 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Actuate Therapeutics by 98.7% in the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company's stock valued at $151,000 after acquiring an additional 11,105 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Actuate Therapeutics in the fourth quarter worth about $130,000.

Actuate Therapeutics Company Profile

(Get Free Report)

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.

Featured Stories

Stock Target Advisor logo

Should You Invest $1,000 in Actuate Therapeutics Right Now?

Before you consider Actuate Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.

While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines